Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

The Sounds of Science podcast is brought to you by GEN. Listen as members of the editorial team—Editor-in-Chief John Sterling, Technical Editor Jeff Buguliskis, and Senior News Editor Alex Philippidis—showcase innovative research, new initiatives, and important policy by interviewing thought-leaders, eminent life-science researchers, and company leaders. These short, but informative podcasts will keep you up-to-date with the latest and most important life science advances.

July 31, 2008

ANTIBIOTICS ENHANCE RNAI CAPABILITIES

- Interview with Peng Jin, Ph.D., Assistant Professor, Department of Human Genetics, Emory University School of Medicine

July 24, 2008

NEW MODEL FOR CREATING A DRUG DISCOVERY COMPANY

- Interview with Ben Conway, Founder and Managing Director, Boston-based Johnston Blakely and Co., and Isaac Ro, Senior Analyst, Boston-based Leerink Swann

July 17, 2008

REVOLUTIONIZING THE PHARMA INDUSTRY VIA VIRTUAL R&D

- Neil Patel, PharmD., Director of Pharmaceutical R&D Operations, PricewaterhouseCoopers

July 10, 2008

NOVEL INSIGHTS INTO CANCER AND THE PROCESS OF AGING

- Interview with Jill Fuss, Ph.D., Research Scientist at Lawrence Berkeley National Laboratory

July 3, 2008

NEW INITIATIVE FOR MAPPING ALL CELL TYPES DERIVED FROM HUMAN EMBRYONIC STEM CELLS

- Interview with Michael West, Ph.D., Chief Executive Officer, BioTime, Inc.

June 26, 2008

NOVEL METHOD FOR REMYELINATING NERVE CELLS

- Interview with Steve Goldman, M.D., Ph.D., Professor of Neurology and Chief of the Division of Cell and Gene Therapy at the University of Rochester Medical Center

June 19, 2008

IMPLICATIONS OF GINA FOR THE BIOTECH AND PHARMA INDUSTRIES

- Interview with Sharon Terry, President and CEO of the Genetic Alliance

June 12, 2008

NOVEL IMMUNE SYSTEM MONITORING TOOL

- Interview with Owen Witte, M.D., Researcher, UCLA Jonsson Cancer Center, and a Howard Hughes Medical Institute Investigator

June 5, 2008

NOVEL COMPOUND MIGHT LEAD TO NEW THERAPY FOR HIGH BLOOD PRESSURE

- Interview with Dr. David Ostrov, from the University of Florida College of Medicine.

May 29, 2008

EVIDENCE-BASED MEDICINE (EBM)

- Interview with Dan Leonard, President of the National Pharmaceutical Council

May 22, 2008

NOVEL APPROACH TO CANCER DRUG DEVELOPMENT

- Interview with Ronen Marmorstein, Ph.D., Professor, Gene Expression and Regulation Program, Wistar Institute

May 15, 2008

GENE THERAPY FOR FATAL NEURODEGENERATIVE DISEASE IN CHILDREN

- Interview with Ronald G. Crystal, M.D., Professor and Chairman of the Department of Genetic Medicine of the Weill Medical College of Cornell University

May 8, 2008

INTERACTING WITH THE FDA-ISSUES AND STRATEGIES

- Interview with Bruce Mackler, Ph.D., J.D., senior advisor on FDA matters and due diligence concerns to financial groups and investment companies

May 1, 2008

TRENDS IN THE GLOBALIZATION OF BIOTECHNOLOGY

- Exclusive GEN Panel Discussion with Four Co-Chairs of the Upcoming Biotechnology Industry Organization's (BIO) Annual International Convention

April 24, 2008

NEW PATH FOR TREATING AND PREVENTING EYE DISEASE

- Interview with Dean Li, M.D.,Ph.D., Professor of Internal Medicine, University of Utah School of Medicine, and Research Scientist with the University's Program in Human Molecular Biology and Genetics

April 17, 2008

miRNAs AND CANCER

- Interview with George Calin, M.D., Ph.D., Associate Professor, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center

April 10, 2008

ADVANCES IN DRUG DELIVERY AND TISSUE ENGINEERING

- Interview with Robert Langer, Ph.D., Institute Professor, Chemical and Biomedical Engineering, MIT

April 3, 2008

BREATH TEST FOR DISEASE DIAGNOSIS

- Interview with Masood Yousef, Ph.D., senior research assistant in the Welsh Centre for Printing and Coating, Swansea University School of Engineering

March 27, 2008

LINKING CHANGES IN GENE NETWORKS TO DISEASE

- Interview with Eric Schadt, Ph.D., Executive Scientific Director of Research Genetics for Rosetta Inpharmatics, Inc., a wholly-owned subsidiary of Merck & Co.